[Modification of the effect of insulin by DL-4 (2-hydroxy-3-isopropylaminopropoxy)-indole (Visken, LB 46) in normal and diabetic persons].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology*; D001786:Blood Glucose; D003920:Diabetes Mellitus / Q000097:blood*; D004357:Drug Synergism; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D005990:Glycerol / Q000097:blood*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013565:Sympatholytics / Q000008:administration & dosage / Q000494:pharmacology*; D014044:Tolbutamide / Q000494:pharmacology
D000605:Amino Alcohols; D001786:Blood Glucose; D005227:Fatty Acids; D007211:Indoles; D007328:Insulin; D013565:Sympatholytics; D014044:Tolbutamide; D005990:Glycerol
Die Beeinflussung der Insulinwirkung durch DL-4-(2-Hydroxy-3-isopropylaminopropoxy)-indol (Visken, LB 46) bei Normalpersonen und Diabetikern.